Merck-Schering Claritin/Singulair Combo “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's review of Singulair safety, centered on suicidal thinking and behavior, at issue.
You may also be interested in...
Merck/Schering Terminate Respiratory Partnership
Firms withdraw NDA for Singulair/Claritin combination.
Merck/Schering Terminate Respiratory Partnership
Firms withdraw NDA for Singulair/Claritin combination.
Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive
FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.